We developed a point-of-care testing method based on lateral flow assay for bevacizumab, using an anti-idiotypic DNA aptamer as the capture molecule. Bevacizumab loaded onto sample pad strip bound to red-colored aptamer-modified gold nanoparticles (AuNPs) in conjugation and then migrated into developing zone. The AuNPs bevacizumab were trapped by protein A test spot. In contrast, excess amounts...
